Previous History of Failed Biologics Associated With Greater Switching in Psoriasis
Higher baseline-PASI and number of previous failed biologic therapies were associated with a greater need for switching in psoriasis.
Psoriasis
Brodalumab Improves Psoriasis in Patients Previously Unresponsive to Therapy
Investigators examined the efficacy of brodalumab, an interleukin-17 receptor-A antagonist to treat moderate to severe psoriasis in patients who had no clinical response with prior anti-interleukin-17A therapies.
Biologic Treatment for Psoriasis Less Likely to Result in Psychiatric Illness
Investigators sought to determine whether persons with psoriasis exposed to biologics are at increased risk for development of a psychiatric illness.
Dermatologists and Pharmacists Define Treatment Persistence in Psoriasis
Investigators examined the scientific opinions of dermatologists and hospital pharmacists to reach a consensus about the effect, causes, and best strategies and interventions related to improved drug persistence in patients with psoriasis in Spain.
Higher Serum Ustekinumab Concentrations May Identify Response in Patients With Psoriasis
Optimal responders had higher concentrations of ustekinumab compared with suboptimal responders.
Effect of Treatment-Emergent Antidrug Antibodies on Safety and Efficacy With Secukinumab for Plaque Psoriasis
Investigators evaluated the effect of neutralizing antibodies or treatment-emergent antidrug antibodies on clinical efficacy and safety of secukinumab in patients with moderate to severe plaque psoriasis.
Infection Risk Lower With Certain Psoriasis Treatments
For patients with psoriasis treated with systemic medications, the risk for serious infection is reduced for new users of apremilast, etanercept, and ustekinumab versus methotrexate.
Ustekinumab Offers Better Drug Survival to Treat Pediatric Psoriasis
Investigators measured the survival rates of biologic therapies in children with psoriasis in real-life conditions, identified factors associated with choice of biologic therapy, and analyzed severe adverse events.
Serious Infection Risk Assessed in Psoriasis Patients Treated With Systemic Meds
According to the results of an observational cohort study, the risk of serious infection may vary significantly among systemic therapies used in the treatment of psoriasis.
Psoriasis Increases Risk for Immune-Mediated Inflammatory Diseases 5-Fold
Because of the lack of previous chronological evaluation, investigators examined the chronology of IMIDs in relation to psoriasis.
Next post in Psoriasis
